Pfizer Australia faces antitrust accusations

18-02-2014

Australia’s antitrust regulator has launched proceedings against Pfizer’s Australian arm, accusing it of abusing its power when supplying cholesterol-lowering drug atorvastatin to pharmacies.


Pfizer Australia, antitrust, ACCC, atorvastatin, anti-competitive

LSIPR